Eric M. Horwitz, MD, FABS, FASTRO

- Request Appointment
- Clinical Locations
- About
- Education and Training
- Patient Stories
- Research Profile
- Publications
- Ratings
Clinical Locations
Primary Location
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Secondary Location
Fox Chase Cancer Center East Norriton-Hospital Outpatient Center
2701 Dekalb Pike
East Norriton, PA 19401
Chair, Department of Radiation Oncology, Lewis Katz School of Medicine at Temple University
Chair, Department of Radiation Oncology, Fox Chase Cancer Center
Professor
Gerald E. Hanks Endowed Chair in Radiation Oncology
NCCN, Prostate Cancer Panel Member
Specialties
Treatment Focus
- Intensity Modulated Radiation Therapy (IMRT)
- Stereotactic body Radiation Therapy (SBRT)
- HDR temporary prostate brachytherapy
- LDR permanent prostate brachytherapy
Research Program
Key Awards
![]() |
Radiation Oncology |
Treatment Philosophy
In addition to my focus on treating and caring for patients with prostate and bladder cancer, it is my responsibility as Chairman of the Department of Radiation Oncology at Fox Chase; an NCI designated National Comprehensive Cancer Center to promote the mission of the Center to prevail over cancer. Our department's expertise has always focused on developing and integrating sophisticated technology into successful treatment for our cancer patients and I remain committed to continuing and expanding this legacy. However, the successful treatment of a patient is not just based on the technology that is available. Being diagnosed with cancer and receiving treatment is one of the most difficult things that many people will ever face, and it is crucial that we as caregivers do not forget this. Caring for patients as one important part of a multidisciplinary team allows us in the Department of Radiation Oncology to provide the best possible care for our patients.
Educational Background
- Resident, Radiation Oncology, William Beaumont Hospital, Royal Oak, MI
- MD, Albany Medical College, Albany, NY, 1992
- BA, History, Chemistry minor, University of Pennsylvania, Philadelphia, PA, 1988
Certifications
- American Board of Radiology, Radiation Oncology
Memberships
- National Comprehensive Cancer Network (NCCN)
- Prostate Cancer Panel
- American Society of Radiation Oncology (ASTRO)
- American Brachytherapy Society (ABS)
- American Board of Radiology (ABR)
- American Medical Association (AMA)
Honors & Awards
- Philadelphia Magazine Top Doctors, 2002, 2005-20
- Best Doctors in America® , 2013-14, 2019-2020, Radiation Oncology
- Inaugural Fellow, American Brachytherapy Society (ABS), 2017
- America’s Top Doctors®, 2015-17
- Newsweek Top Cancer Doctors, 2015
- Volunteer Service Award, American Board of Radiology, 2014
- Distinguished Service Award, American Brachytherapy Society, 2010
Research Program
Research Interests
- Determining outcomes in treatment for prostate cancer patients treated with external beam radiation and brachytherapy
- Developing image guidance techniques for prostate cancer radiation
- Developing new bladder preservation techniques to treat patients with muscle invasive bladder cancer
Selected Publications
Rosenthal SA, Hu C, Sartor O, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Horwitz EM, Raben A, Peters CA, Feng FY, Shipley WU, Sandler HM. Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology:Jco1802158, 2019. PubMed
Martin, J.M., Li, T., Johnson, M.E., Murphy, C.T., Howald, A.G., Smaldone, M.C., Kutikov, A., Chen, D.Y., Viterbo, R., Greenberg, R.E., Uzzo, R.G., Horwitz, E.M. Use of Postprostatectomy Radiation Therapy at an NCI-Designated Comprehensive Cancer Center. J Natl Compr Canc Netw 13: 525-30; 2015. PubMed
Horwitz, E.M. and Weinberg, D.S. Medicare physician payment data: Is this transparency? Ann. Int. Med. 161(4): 291-292; 2014. PubMed
Horwitz EM. ABS brachytherapy consensus guidelines. Brachytherapy. 11(1): 4-5, 2012. PubMed
Davis BJ, Horwitz EM, Lee WR, Crook, J. M.; Stock, R. G.; Merrick, G. S.; Butler, W. M.; Grimm, P. D.; Stone, N. N.; Potters, L.; Zietman, A. L.; Zelefsky, M. J. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy 11(1):6-19, 2012. PubMed
Crook, J.M.; O'Callaghan, C.J.; Duncan, G.; Dearnaley, D.P.; Higano, C.S.; Horwitz, E.M.; Frymire, E.; Malone, S.; Chin, J.; Nabid, A.; Warde, P.; Corbett, T.; Angyalfi, S.; Goldenberg, S.L.; Gospodarowicz, M.K.; Saad, F.; Logue, J.P.; Hall, E.; Schellhammer, P.F.; Ding, K.; Klotz, L. Intermittent androgen suppression for rising PSA level after radiotherapy. New England Journal of Medicine 367: 895-903; 2012. PubMed
Rosenthal, S.A.; Bittner, N.H.; Beyer, D.C.; Demanes, D.J.; Goldsmith, B.J.; Horwitz, E.M.; Ibbott, G.S.; Lee, W.R.; Nag, S.; Suh, W.W.; Potters, L. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer. International Journal of Radiation Oncology Biology Physics 79: 335-41; 2011. PubMed
Horwitz, E.M. Why External Beam Radiotherapy Is Treatment of Choice for Most Men With Early-stage Nonmetastatic Prostate Cancer. Urology 73: 470-472; 2009. PubMed
Horwitz, E.M.; Bae, K.; Hanks, G.E.; Porter, A.; Grignon, D.; Brereton, H.; Venkatesan, V.; Lawton, C.A.; Rosenthal, S.A.; Sandler, H.M.; Shipley, W.U. Ten-Year Follow-Up of RTOG 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer. Journal of Clinical Oncology 26: 2497-2504; 2008. PubMed
Langer, C.J.; Harris, J.; Horwitz, E.M.; Nicolaou, N.; Kies, M.; Curran, W.J.; Wong, S.J.; Ang, K.K. Phase II study of paclitaxel, cisplatin in combination with split course concomitant hyperfractionated re-irradiation in patients with recurrent squamous cell cancer of the head and neck cancer: Preliminary results of RTOG 99-11. Journal of Clinical Oncology 25: 4800-4805; 2007. PubMed
Horwitz, E.M.; Levy, L.B.; Thames, H.D.; Kuban, D.A.; Kupelian, P.A.; Martinez, A.A.; Michalski, J.M.; Pisansky T.M.; Sandler, H.M.; Shipley, W.U.; Zelefsky, M.J.; Hanks, G.E.; Zietman, A.L. The Biochemical And Clinical Significance Of The Post-Treatment PSA Bounce For Prostate Cancer Patients Treated With External Beam Radiation Therapy Alone: A Multi-Institutional Pooled Analysis. Cancer 1071: 1496-1502; 2006. PubMed
Kuban, D.A.; Levy, L.B.; Potters, L.; Beyer, D.C.; Blasko, J.C.; Moran, B.J.; Ciezki, J.P.; Zietman, A.L.; Zelefsky, M.J.; Pisansky, T.M.; Elshaikh, M.; Horwitz, E.M. Comparison of biochemical failure definitions for permanent prostate brachytherapy. International Journal of Radiation Oncology Biology and Physics 65: 1487-1493; 2006. PubMed
Horwitz, E.M.; Thames, H.D.; Kuban, D.A.; Levy, L.B.; Kupelian, P.A.; Martinez, A.A.; Michalski, J.M.; Pisansky T.M.; Sandler, H.M.; Shipley, W.U.; Zelefsky, M.J.; Hanks, G.E.; Zietman, A.L. Definitions Of Biochemical Failure That Best Predict Clinical Failure In Prostate Cancer Patients Treated With External Beam Radiation Alone - A Multi-Institutional Pooled Analysis. Journal of Urology 173:797-802; 2005. PubMed
Horwitz, E.M.; Uzzo, R.G.; Hanlon, A.L.; Greenberg, R.E.; Hanks, G.E.; Pollack, A. Modifying the ASTRO definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3D conformal radiation therapy alone. Journal of Urology 169: 2153-2159; 2003. PubMed
Hanks, G.E.; Hanlon, A.L.; Epstein, B.; Horwitz, E.M. Dose response in prostate cancer with 8-12 year follow-up. International Journal of Radiation Oncology Biology and Physics 54: 427-435; 2002. PubMed
Additional Publications

Clinical Locations
Primary Location
Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111
Secondary Location
Fox Chase Cancer Center East Norriton-Hospital Outpatient Center
2701 Dekalb Pike
East Norriton, PA 19401
Chair, Department of Radiation Oncology, Lewis Katz School of Medicine at Temple University
Chair, Department of Radiation Oncology, Fox Chase Cancer Center
Professor
Gerald E. Hanks Endowed Chair in Radiation Oncology
NCCN, Prostate Cancer Panel Member
Treatment Focus
- Intensity Modulated Radiation Therapy (IMRT)
- Stereotactic body Radiation Therapy (SBRT)
- HDR temporary prostate brachytherapy
- LDR permanent prostate brachytherapy
Research Program
Key Awards
![]() |
Radiation Oncology |
Treatment Philosophy
In addition to my focus on treating and caring for patients with prostate and bladder cancer, it is my responsibility as Chairman of the Department of Radiation Oncology at Fox Chase; an NCI designated National Comprehensive Cancer Center to promote the mission of the Center to prevail over cancer. Our department's expertise has always focused on developing and integrating sophisticated technology into successful treatment for our cancer patients and I remain committed to continuing and expanding this legacy. However, the successful treatment of a patient is not just based on the technology that is available. Being diagnosed with cancer and receiving treatment is one of the most difficult things that many people will ever face, and it is crucial that we as caregivers do not forget this. Caring for patients as one important part of a multidisciplinary team allows us in the Department of Radiation Oncology to provide the best possible care for our patients.
Education
Educational Background
- Resident, Radiation Oncology, William Beaumont Hospital, Royal Oak, MI
- MD, Albany Medical College, Albany, NY, 1992
- BA, History, Chemistry minor, University of Pennsylvania, Philadelphia, PA, 1988
Certifications
- American Board of Radiology, Radiation Oncology
Memberships
- National Comprehensive Cancer Network (NCCN)
- Prostate Cancer Panel
- American Society of Radiation Oncology (ASTRO)
- American Brachytherapy Society (ABS)
- American Board of Radiology (ABR)
- American Medical Association (AMA)
Honors & Awards
- Philadelphia Magazine Top Doctors, 2002, 2005-20
- Best Doctors in America® , 2013-14, 2019-2020, Radiation Oncology
- Inaugural Fellow, American Brachytherapy Society (ABS), 2017
- America’s Top Doctors®, 2015-17
- Newsweek Top Cancer Doctors, 2015
- Volunteer Service Award, American Board of Radiology, 2014
- Distinguished Service Award, American Brachytherapy Society, 2010
Research Profile
Research Interests
- Determining outcomes in treatment for prostate cancer patients treated with external beam radiation and brachytherapy
- Developing image guidance techniques for prostate cancer radiation
- Developing new bladder preservation techniques to treat patients with muscle invasive bladder cancer
Publications
Selected Publications
Rosenthal SA, Hu C, Sartor O, Gomella LG, Amin MB, Purdy J, Michalski JM, Garzotto MG, Pervez N, Balogh AG, Rodrigues GB, Souhami L, Reaume MN, Williams SG, Hannan R, Horwitz EM, Raben A, Peters CA, Feng FY, Shipley WU, Sandler HM. Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology:Jco1802158, 2019. PubMed
Martin, J.M., Li, T., Johnson, M.E., Murphy, C.T., Howald, A.G., Smaldone, M.C., Kutikov, A., Chen, D.Y., Viterbo, R., Greenberg, R.E., Uzzo, R.G., Horwitz, E.M. Use of Postprostatectomy Radiation Therapy at an NCI-Designated Comprehensive Cancer Center. J Natl Compr Canc Netw 13: 525-30; 2015. PubMed
Horwitz, E.M. and Weinberg, D.S. Medicare physician payment data: Is this transparency? Ann. Int. Med. 161(4): 291-292; 2014. PubMed
Horwitz EM. ABS brachytherapy consensus guidelines. Brachytherapy. 11(1): 4-5, 2012. PubMed
Davis BJ, Horwitz EM, Lee WR, Crook, J. M.; Stock, R. G.; Merrick, G. S.; Butler, W. M.; Grimm, P. D.; Stone, N. N.; Potters, L.; Zietman, A. L.; Zelefsky, M. J. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy 11(1):6-19, 2012. PubMed
Crook, J.M.; O'Callaghan, C.J.; Duncan, G.; Dearnaley, D.P.; Higano, C.S.; Horwitz, E.M.; Frymire, E.; Malone, S.; Chin, J.; Nabid, A.; Warde, P.; Corbett, T.; Angyalfi, S.; Goldenberg, S.L.; Gospodarowicz, M.K.; Saad, F.; Logue, J.P.; Hall, E.; Schellhammer, P.F.; Ding, K.; Klotz, L. Intermittent androgen suppression for rising PSA level after radiotherapy. New England Journal of Medicine 367: 895-903; 2012. PubMed
Rosenthal, S.A.; Bittner, N.H.; Beyer, D.C.; Demanes, D.J.; Goldsmith, B.J.; Horwitz, E.M.; Ibbott, G.S.; Lee, W.R.; Nag, S.; Suh, W.W.; Potters, L. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer. International Journal of Radiation Oncology Biology Physics 79: 335-41; 2011. PubMed
Horwitz, E.M. Why External Beam Radiotherapy Is Treatment of Choice for Most Men With Early-stage Nonmetastatic Prostate Cancer. Urology 73: 470-472; 2009. PubMed
Horwitz, E.M.; Bae, K.; Hanks, G.E.; Porter, A.; Grignon, D.; Brereton, H.; Venkatesan, V.; Lawton, C.A.; Rosenthal, S.A.; Sandler, H.M.; Shipley, W.U. Ten-Year Follow-Up of RTOG 92-02: A Phase III Trial of the Duration of Elective Androgen Deprivation in Locally Advanced Prostate Cancer. Journal of Clinical Oncology 26: 2497-2504; 2008. PubMed
Langer, C.J.; Harris, J.; Horwitz, E.M.; Nicolaou, N.; Kies, M.; Curran, W.J.; Wong, S.J.; Ang, K.K. Phase II study of paclitaxel, cisplatin in combination with split course concomitant hyperfractionated re-irradiation in patients with recurrent squamous cell cancer of the head and neck cancer: Preliminary results of RTOG 99-11. Journal of Clinical Oncology 25: 4800-4805; 2007. PubMed
Horwitz, E.M.; Levy, L.B.; Thames, H.D.; Kuban, D.A.; Kupelian, P.A.; Martinez, A.A.; Michalski, J.M.; Pisansky T.M.; Sandler, H.M.; Shipley, W.U.; Zelefsky, M.J.; Hanks, G.E.; Zietman, A.L. The Biochemical And Clinical Significance Of The Post-Treatment PSA Bounce For Prostate Cancer Patients Treated With External Beam Radiation Therapy Alone: A Multi-Institutional Pooled Analysis. Cancer 1071: 1496-1502; 2006. PubMed
Kuban, D.A.; Levy, L.B.; Potters, L.; Beyer, D.C.; Blasko, J.C.; Moran, B.J.; Ciezki, J.P.; Zietman, A.L.; Zelefsky, M.J.; Pisansky, T.M.; Elshaikh, M.; Horwitz, E.M. Comparison of biochemical failure definitions for permanent prostate brachytherapy. International Journal of Radiation Oncology Biology and Physics 65: 1487-1493; 2006. PubMed
Horwitz, E.M.; Thames, H.D.; Kuban, D.A.; Levy, L.B.; Kupelian, P.A.; Martinez, A.A.; Michalski, J.M.; Pisansky T.M.; Sandler, H.M.; Shipley, W.U.; Zelefsky, M.J.; Hanks, G.E.; Zietman, A.L. Definitions Of Biochemical Failure That Best Predict Clinical Failure In Prostate Cancer Patients Treated With External Beam Radiation Alone - A Multi-Institutional Pooled Analysis. Journal of Urology 173:797-802; 2005. PubMed
Horwitz, E.M.; Uzzo, R.G.; Hanlon, A.L.; Greenberg, R.E.; Hanks, G.E.; Pollack, A. Modifying the ASTRO definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3D conformal radiation therapy alone. Journal of Urology 169: 2153-2159; 2003. PubMed
Hanks, G.E.; Hanlon, A.L.; Epstein, B.; Horwitz, E.M. Dose response in prostate cancer with 8-12 year follow-up. International Journal of Radiation Oncology Biology and Physics 54: 427-435; 2002. PubMed
37 PATIENT COMMENTS